Research progress on the impact of liver metastasis on the efficacy of immunotherapy for lung cancer

doi:10.3760/cma.j.cn371439-20260108-00107

Abstract

Abstract:

Lung cancer ranks among the top malignancies in terms of both incidence and mortality rates. The liver is a common site of distant metastasis， which is closely associated with the poor prognosis. In recent years， immune checkpoint inhibitors （ICIs） have achieved significant breakthroughs in the treatment of advanced lung cancer. Patients with liver metastasis can also benefit from ICI therapy. However， compared to the overall population， the presence of liver metastasis remains an independent prognostic factor for poor efficacy of immunotherapy. Based on recent research， summarizing the impact of liver metastasis on the efficacy of immunotherapy for lung cancer， the underlying mechanisms， and future research directions may provide certain reference basis for formulating comprehensive treatment strategies for lung cancer patients with liver metastasis.

Key words: Lung neoplasms, Neoplasm metastasis, Immunotherapy, Tumor microenvironment

Luo Liangxue, Zhao Chaofen, Su Shengfa. Research progress on the impact of liver metastasis on the efficacy of immunotherapy for lung cancer[J]. Journal of International Oncology, 2026, 53(11): 688-693.

References 45

[1]	Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73(1): 17-48. DOI: 10.3322/caac.21763.
[2]	Quint LE, Tummala S, Brisson LJ, et al. Distribution of distant metastases from newly diagnosed non-small cell lung cancer[J]. Ann Thorac Surg, 1996, 62(1): 246-250. DOI: 10.1016/0003-4975(96)00220-2. pmid: 8678651
[3]	Riihimäki M, Hemminki A, Fallah M, et al. Metastatic sites and survival in lung cancer[J]. Lung Cancer, 2014, 86(1): 78-84. DOI: 10.1016/j.lungcan.2014.07.020. pmid: 25130083
[4]	Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC[J]. N Engl J Med, 2018, 378(24): 2288-2301. DOI: 10.1056/NEJMoa1716948.
[5]	Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive- stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial[J]. Lancet, 2019, 394(10212): 1929-1939. DOI: 10.1016/S0140-6736(19)32222-6. pmid: 31590988
[6]	Komiya T, Takamori S, Shimokawa M. Impact of liver metastasis on first-line immunotherapy in stage Ⅳ non-small cell lung cancer[J]. World J Oncol, 2023, 14(4): 234-245. DOI: 10.14740/wjon1625.
[7]	Xiao Q, Yu X, Shuai Z, et al. The influence of baseline characteristics on the efficacy of immune checkpoint inhibitors for advanced lung cancer: a systematic review and meta-analysis[J]. Front Pharmacol, 2022, 13: 956788. DOI: 10.3389/fphar.2022.956788.
[8]	Antonia SJ, Balmanoukian A, Brahmer J, et al. Clinical activity, tolerability, and long-term follow-up of Durvalumab in patients with advanced NSCLC[J]. J Thorac Oncol, 2019, 14(10): 1794-1806. DOI: 10.1016/j.jtho.2019.06.010. pmid: 31228626
[9]	Garassino MC, Cho BC, Kim JH, et al. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study[J]. Lancet Oncol, 2018, 19(4): 521-536. DOI: 10.1016/S1470-2045(18)30144-X. pmid: 29545095
[10]	Vokes EE, Ready N, Felip E, et al. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases[J]. Ann Oncol, 2018, 29(4): 959-965. DOI: 10.1093/annonc/mdy041. pmid: 29408986
[11]	Reck M, Mok TSK, Nishio M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial[J]. Lancet Respir Med, 2019, 7(5): 387-401. DOI: 10.1016/S2213-2600(19)30084-0. pmid: 30922878
[12]	Choi MG, Choi CM, Lee DH, et al. Different prognostic implications of hepatic metastasis according to front-line treatment in non-small cell lung cancer: a real-world retrospective study[J]. Transl Lung Cancer Res, 2021, 10(6): 2551-2561. DOI: 10.21037/tlcr-21-206.
[13]	Nishio M, Barlesi F, West H, et al. Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 IMpower132 trial[J]. J Thorac Oncol, 2021, 16(4): 653-664. DOI: 10.1016/j.jtho.2020.11.025.
[14]	West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2019, 20(7): 924-937. DOI: 10.1016/S1470-2045(19)30167-6. pmid: 31122901
[15]	Deng JY, Gou Q, Yang L, et al. Immune suppressive microenvironment in liver metastases contributes to organ-specific response of immunotherapy in advanced non-small cell lung cancer[J]. J Immunother Cancer, 2023, 11(7): e007218. DOI: 10.1136/jitc-2023-007218.
[16]	中国临床肿瘤学会小细胞肺癌专家委员会, 中国医师协会肿瘤多学科诊疗专业委员会. 小细胞肺癌免疫治疗专家共识(2025版)[J]. 中华肿瘤杂志, 2025, 47(1): 65-75. DOI: 10.3760/cma.j.cn112152-20240905-00383.
[17]	Horn L, Mansfield AS, Szczęsna A, et al. First-line Atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer[J]. N Engl J Med, 2018, 379(23): 2220-2229. DOI: 10.1056/NEJMoa1809064.
[18]	Wang J, Zhou C, Yao W, et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2022, 23(6): 739-747. DOI: 10.1016/S1470-2045(22)00224-8. pmid: 35576956
[19]	Rudin CM, Awad MM, Navarro A, et al. Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase Ⅲ KEYNOTE-604 study[J]. J Clin Oncol, 2020, 38(21): 2369-2379. DOI: 10.1200/JCO.20.00793.
[20]	Lin Y, Jiang W, Su CY, et al. Impact of liver metastases status on survival outcomes of first-line immunotherapy in extensive stage small cell lung cancer: a systematic review and meta-analysis[J]. Aging (Albany NY), 2023, 15(18): 9561-9571. DOI: 10.18632/aging.205035.
[21]	Cheng Y, Zhang S, Han L, et al. First-line serplulimab plus chemotherapy in extensive-stage small-cell lung cancer: updated results and biomarker analysis from the ASTRUM-005 randomized clinical trial[J]. Cancer Commun (Lond), 2025, 45(8): 990-1009. DOI: 10.1002/cac2.70032.
[22]	Cheng Y, Chen J, Zhang W, et al. Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial[J]. Nat Med, 2024, 30(10): 2967-2976. DOI: 10.1038/s41591-024-03132-1. pmid: 38992123
[23]	Bolte FJ, Dougherty SC, Danos AO, et al. Real-world outcomes of tarlatamab in small cell lung cancer, including patients with untreated brain metastases[J]. Clin Lung Cancer, 2025, 26(5): 347-353.e1. DOI: 10.1016/j.cllc.2025.03.006.
[24]	Sagie S, Maixner N, Stemmer A, et al. Real-world evidence for immunotherapy in the first line setting in small cell lung cancer[J]. Lung Cancer, 2022, 172: 136-141. DOI: 10.1016/j.lungcan.2022.08.015. pmid: 36087486
[25]	Yamanaka Y, Okuno Y, Kamisako K, et al. Efficacy and safety evaluation of immune checkpoint inhibitors in combination with chemotherapy for extensive small cell lung cancer: real-world evidence[J]. Cancer Med, 2024, 13(24): e70480. DOI: 10.1002/cam4.70480.
[26]	Li X, Ramadori P, Pfister D, et al. The immunological and metabolic landscape in primary and metastatic liver cancer[J]. Nat Rev Cancer, 2021, 21(9): 541-557. DOI: 10.1038/s41568-021-00383-9. pmid: 34326518
[27]	Yu J, Green MD, Li S, et al. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination[J]. Nat Med, 2021, 27(1): 152-164. DOI: 10.1038/s41591-020-1131-x. pmid: 33398162
[28]	Li Q, Zhao R, Shen Y, et al. Lactylation in tumor immune escape and immunotherapy: multifaceted functions and therapeutic strategies[J]. Research (Wash D C), 2025, 8: 0793. DOI: 10.34133/research.0793. pmid: 40948941
[29]	He LN, Fu S, Zhang X, et al. Baseline and early changes in circulating Serum Amyloid A (SAA) predict survival outcomes in advanced non-small cell lung cancer patients treated with anti-PD-1/PD-L1 monotherapy[J]. Lung Cancer, 2021, 158: 1-8. DOI: 10.1016/j.lungcan.2021.05.030.
[30]	Yang J, Yamashita-Kanemaru Y, Morris BI, et al. Aspirin prevents metastasis by limiting platelet TXA2 suppression of T cell immunity[J]. Nature, 2025, 640(8060): 1052-1061. DOI: 10.1038/s41586-025-08626-7.
[31]	Zhang T, Li Y, Cheng B, et al. Piezo1 activation improves NSCLC liver metastasis immunotherapy by overriding matrix stiffness-mediated bimodal PD-L1/CXCL10 regulation[J]. Adv Sci (Weinh), 2025, 12(32): e01335. DOI: 10.1002/advs.202501335.
[32]	Lou L, Peng K, Ouyang S, et al. Periostin-mediated NOTCH1 activation between tumor cells and HSCs crosstalk promotes liver metastasis of small cell lung cancer[J]. J Exp Clin Cancer Res, 2025, 44(1): 6. DOI: 10.1186/s13046-024-03266-7. pmid: 39762921
[33]	Catanzaro E, Beltrán-Visiedo M, Galluzzi L, et al. Immunogenicity of cell death and cancer immunotherapy with immune checkpoint inhibitors[J]. Cell Mol Immunol, 2025, 22(1): 24-39. DOI: 10.1038/s41423-024-01245-8. pmid: 39653769
[34]	黄华玉, 龚虹云, 宋启斌. 胸部放疗联合免疫治疗时代肺炎发生的影响因素[J]. 国际肿瘤学杂志, 2023, 50(2): 102-106. DOI: 10.3760/cma.j.cn371439-20221115-00021.
[35]	Sun M, Ji H, Deng F, et al. Clinical outcomes and synergistic effect between radiotherapy and immunotherapy in patients with extensive-stage small cell lung cancer: a real-world study[J]. BMC Cancer, 2024, 24(1): 1206. DOI: 10.1186/s12885-024-12942-y. pmid: 39350057
[36]	Zhang J, Huang D, Saw PE, et al. Turning cold tumors hot: from molecular mechanisms to clinical applications[J]. Trends Immunol, 2022, 43(7): 523-545. DOI: 10.1016/j.it.2022.04.010. pmid: 35624021
[37]	Sharma P, Goswami S, Raychaudhuri D, et al. Immune checkpoint therapy-current perspectives and future directions[J]. Cell, 2023, 186(8): 1652-1669. DOI: 10.1016/j.cell.2023.03.006. pmid: 37059068
[38]	Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy[J]. Immunity, 2020, 52(1): 17-35. DOI: 10.1016/j.immuni.2019.12.011. pmid: 31940268
[39]	Shi W, Yang X, Xie S, et al. A new PD-1-specific nanobody enhances the antitumor activity of T-cells in synergy with dendritic cell vaccine[J]. Cancer Lett, 2021, 522: 184-197. DOI: 10.1016/j.canlet.2021.09.028. pmid: 34562519
[40]	Fritsch EF, Ott PA. Personalized cancer vaccines directed against tumor mutations: building evidence from mice to humans[J]. Cancer Res, 2024, 84(7): 953-955. DOI: 10.1158/0008-5472.CAN-24-0565. pmid: 38558128
[41]	Zhao W, Li B, Gu Y, et al. The efficacy and safety of immune combination therapy in patients with driver gene-negative non-small cell lung cancer with liver metastasis: a systematic review and network meta-analysis[J]. BMC Cancer, 2025, 25(1): 1332. DOI: 10.1186/s12885-025-14712-w. pmid: 40826400
[42]	Lu S, Stein JE, Rimm DL, et al. Comparison of biomarker modalities for predicting response to PD-1/PD-L1 checkpoint blockade: a systematic review and meta-analysis[J]. JAMA Oncol, 2019, 5(8): 1195-1204. DOI: 10.1001/jamaoncol.2019.1549.
[43]	Zhang Y, Li W, Zhang W, et al. Low-dose radiotherapy combined with chemoimmunotherapy yields superior survival outcomes compared with chemoimmunotherapy alone for patients with small cell lung cancer with liver metastasis: a retrospective study[J]. BMC Cancer, 2025, 25(1): 1785. DOI: 10.1186/s12885-025-15212-7.
[44]	Zhao G, Liu S, Liu Y, et al. CalliSpheres^® microsphere transarterial chemoembolization combined with ¹²⁵I brachytherapy for patients with non-small-cell lung cancer liver metastases[J]. Front Oncol, 2022, 12: 882061. DOI: 10.3389/fonc.2022.882061.
[45]	Qu FJ, Zhou Y, Wu S. Progress of immune checkpoint inhibitors therapy for non-small cell lung cancer with liver metastases[J]. Br J Cancer, 2024, 130(2): 165-175. DOI: 10.1038/s41416-023-02482-w.